natgillin/translations-raw huggingface dataset:
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Alofisel have also been included in the summary of product characteristics and the package leaflet.
Priporočila in varnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Alofisel upoštevati zdravstveni delavci in bolniki, so vključeni tudi v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo.
The company that markets Alofisel will provide educational material for healthcare professionals on how to give the medicine correctly and on the possibility of passing on an infection to the patient.
Družba, ki trži zdravilo Alofisel, bo zdravstvenim delavcem priskrbela izobraževalno gradivo o pravilnem dajanju zdravila in možnosti prenosa okužbe na bolnika.
What is Alofisel and what is it used for?
Kaj je zdravilo Alofisel in za kaj se uporablja?
What benefits of Alofisel have been shown in studies?
Kakšne koristi je zdravilo Alofisel izkazalo v študijah?
Why is Alofisel approved?
Zakaj je bilo zdravilo Alofisel odobreno?
Alofisel should be given only by specialist doctors experienced in the diagnosis and treatment of the condition for which it is used.
Zdravilo Alofisel smejo dajati samo zdravniki specialisti z izkušnjami v diagnostiki in zdravljenju bolezni, za katero se uporablja.
For more information about treatment with Alofisel, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Za več informacij o zdravljenju z zdravilom Alofisel preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
Complex fistulas are those with several abnormal passages and openings, or with passages that go deep inside the body, or where there are other complications such as collection of pus.
Zapletene fistule so fistule z več nenormalnimi prehodi in odprtinami ali s prehodi, ki segajo globoko v telo, ali stanja z več zapleti, kot so ognojki.
The full EPAR for Alofisel can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Alofisel je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
One main study, involving 212 patients with Crohn's disease and complex anal fistulas, found Alofisel more effective than placebo (a dummy treatment) 24 weeks after treatment.
V glavni študiji, ki je vključevala 212 bolnikov s Crohnovo boleznijo in zapletenimi analnimi fistulami, so ugotovili, da je zdravilo Alofisel po 24 tednih zdravljenja učinkovitejše od placeba (zdravila brez zdravilne učinkovine).
It is a type of advanced therapy medicine called a ‘somatic cell therapy product'.
Zdravilo spada v skupino zdravil za napredno zdravljenje, ki se imenujejo „zdravila za somatsko celično zdravljenje“.
Alofisel is of value in the treatment of complex anal fistulas that have not responded well to other treatments.
Zdravilo Alofisel je pomembno pri zdravljenju zapletenih analnih fistul, ki se ne odzovejo na druga zdravljenja.
Fistulas are abnormal passages between the lower parts of the gut and the skin near the anus.
Fistule so nenormalni prehodi med spodnjimi deli črevesja in kožo v analnem predelu.
Alofisel is a medicine that is used to treat complex anal fistulas in adults with Crohn's disease (an inflammatory condition of the gut) when a conventional or biological medicine has not worked well enough.
Zdravilo Alofisel se uporablja pri zdravljenju zapletenih analnih fistul pri odraslih s Crohnovo boleznijo (črevesno vnetno boleznijo), kadar konvencionalna ali biološka zdravila niso dovolj učinkovita.
For practical information about using Alofisel, patients should read the package leaflet or contact their doctor or pharmacist.
Za praktične informacije o uporabi zdravila Alofisel naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
The most common side effects with Alofisel (which may affect up to 1 in 10 people) are anal abscess (a swollen area with a collection of pus), proctalgia (anal pain), anal fistula and pain during treatment.
Najpogostejši neželeni učinki zdravila Alofisel (ki se lahko pojavijo pri največ 1 bolniku od 10) so analni absces (oteklina z ognojkom), proktalgija (analna bolečina), analna fistula in bolečine med zdravljenjem.
Alofisel contains the active substance darvadstrocel, which comprises stem cells removed from fat tissue of adult donors.
Zdravilo Alofisel vsebuje zdravilno učinkovino darvadstrocel, ki je sestavljeno iz matičnih celic, pridobljenih iz maščobnega tkiva odraslih darovalcev.
How is Alofisel used?
Kako se zdravilo Alofisel uporablja?
Alofisel is made up of ‘mesenchymal stem cells' from the fat tissue of a donor.
Zdravilo Alofisel je narejeno iz mezenhimskih matičnih celic, pridobljenih iz maščobnega tkiva darovalca.
How does Alofisel work?
Kako zdravilo Alofisel deluje?
30 film-coated tablets in blisters
30 filmsko obloženih tablet v pretisnih omotih
The marketing authorisation was renewed on 18 August 2003 and on 18 August 2008.
Dovoljenje za promet z zdravilom je bilo obnovljeno 18. avgusta 2003 in 18. avgusta 2008.
The dose is adjusted to give the best control.
Odmerek se prilagodi, da se omogoči čim boljši nadzor.
The European Commission granted a marketing authorisation valid throughout the European Union for Prandin to Novo Nordisk A/S on 29 January 2001.
Evropska komisija je dovoljenje za promet z zdravilom Prandin, veljavno po vsej Evropski uniji, odobrila družbi Novo Nordisk A/S dne 29. januarja 2001.
Prandin is not recommended for patients below 18 years of age because of a lack of information on safety and effectiveness in this age group.
Zdravilo Prandin ni priporočljivo za bolnike, mlajše od 18 let, zaradi pomanjkanja informacij o varnosti in učinkovitosti zdravila v tej starostni skupini.
Prandin is taken before meals, normally up to 15 minutes before each main meal.
Zdravilo Prandin se jemlje pred obroki, običajno do 15 minut pred vsakim glavnim obrokom.
Other information about Prandin:
Druge informacije o zdravilu Prandin:
It is available as round tablets (white: 0.5 mg; yellow: 1 mg; peach: 2 mg).
Na voljo je v obliki okroglih tablet (bele: 0,5 mg; rumene: 1 mg: barve breskve: 2 mg).
If patients are transferred from another anti-diabetes medicine, the recommended starting dose is 1 mg.
Če bolniki preidejo z drugega antidiabetičnega zdravila, je priporočeni začetni odmerek 1 mg.
What benefit has Prandin shown during the studies?
Kakšne koristi je zdravilo Prandin izkazalo med študijami?
Prandin is a medicine that contains the active substance repaglinide.
Prandin je zdravilo, ki vsebuje zdravilno učinkovino repaglinid.
If you need more information about your medical condition or your treatment, read the Package Leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Če potrebujete več informacij o svojem zdravstvenem stanju ali zdravljenju, preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujete s svojim zdravnikom ali farmacevtom.
Another study looked at the effect of adding Prandin to metformin.
Druga študija je preučevala učinek dodajanja zdravila Prandin k metforminu.
EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR) PRANDIN EPAR summary for the public
EVROPSKO JAVNO POROČILO O OCENI ZDRAVILA (EPAR) PRANDIN Povzetek EPAR za javnost
The Committee recommended that Prandin be given marketing authorisation.
Odbor je priporočil, da se za zdravilo Prandin odobri dovoljenje za promet.
The raised insulin levels returned to normal after the meal.
Zvečana koncentracija insulina se je po obroku vrnila na normalno raven.
A doctor should regularly test the patient's blood glucose to find the lowest effective dose.
Zdravnik mora redno preverjati bolnikovo glukozo v krvi, da določi najmanjši učinkoviti odmerek.
Prandin has been studied in 45 ‘clinical pharmacology' studies (looking at how the medicine works in the body) and 16 clinical trials (looking at its effects in treating type 2 diabetes patients).
Zdravilo Prandin so preučevali v 45 kliničnih farmakoloških študijah (v katerih so preučevali, kako zdravilo deluje v telesu) in 16 kliničnih preskušanjih (v katerih so preučevali njegove učinke pri zdravljenju bolnikov s sladkorno boleznijo tipa 2).
In the study where Prandin was added to metformin, the effects of the two medicines were at least additive (equivalent to the effects of the two medicines added together).
V študijah, v katerih so zdravilo Prandin dodali metforminu, so bili učinki dveh zdravil najmanjši (enaki učinkom dveh zdravil, dodanih skupaj).
Prandin should not be used in people who may be hypersensitive (allergic) to repaglinide or any of the other ingredients.
Zdravila Prandin ne smejo uporabljati osebe, ki utegnejo biti preobčutljive za (alergične na) repaglinid ali katero koli drugo sestavino zdravila.
A total of 2,156 patients received Prandin in all trials combined.
V vseh preskušanjih skupaj je zdravilo Prandin prejelo 2156 bolnikov.
Prandin doses may also need to be adjusted when given with some medicines used in heart conditions, and to treat pain, asthma and other conditions.
Odmerke zdravila Prandin bo morda treba tudi prilagoditi, če se uporabljajo z zdravili za zdravljenje bolezni srca, bolečin, astme in drugih bolezni.
The main studies compared Prandin with other medicines used in type 2 diabetes (glibenclamide, glipizide or gliclazide).
V glavnih študijah so zdravilo Prandin primerjali z drugimi zdravili, uporabljenimi za zdravljenje sladkorne bolezni tipa 2 (glibenklamid, glipizid ali gliklazid).
What is the risk associated with Prandin?
Kakšna tveganja so povezana z zdravilom Prandin?
Why has Prandin been approved?
Zakaj je bilo zdravilo Prandin odobreno?
Type 2 diabetes is a disease in which the pancreas does not make enough insulin to control the level of glucose in the blood or when the body is unable to use insulin effectively.
Sladkorna bolezen tipa 2 je bolezen, pri kateri trebušna slinavka ne tvori dovolj insulina za uravnavanje koncentracije glukoze v krvi ali kadar telo ne more učinkovito izrabljati insulina.
It should also not be used in patients with diabetic ketoacidosis (high levels of ketones [acids] in the blood), in patients with severe liver problems or in patients also taking gemfibrozil (a medicine used to reduce blood fat levels).
Uporabljati se ne sme tudi pri bolnikih z diabetično ketoacidozo (visoko koncentracijo ketonov [kislin] v krvi), bolnikih z hudimi težavami z jetri ali bolnikih, ki jemljejo tudi gemfibrozil (zdravilo, ki se uporablja za zniževanje ravni maščob v krvi).
The Committee for Medicinal Products for Human Use (CHMP) decided that Prandin's benefits are greater than its risks for the treatment of type 2 diabetes.
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi zdravila Prandin za zdravljenje sladkorne bolezni tipa 2 večje od z njim povezanih tveganj.
The most common side effects with Prandin (seen in between 1 and 10 patients in 100) are hypoglycaemia (low blood glucose levels), abdominal (tummy) pain and diarrhoea.
Najpogostejši neželeni učinki zdravila Prandin (opaženi pri 1 do 10 bolnikih izmed 100) so hipoglikemija (nizka koncentracija glukoze v krvi), bolečine v trebuhu in driska.
This dose may need to be increased after one or two weeks.
Priporočeni začetni odmerek je 0,5 mg. Odmerek bo morda treba po enem ali dveh tednih povečati.
It should also not be used in patients with type 1 (insulin-dependent) diabetes who do not have any ‘C-peptide' in their blood (a marker of type 1 diabetes).
Prav tako ga ne smejo uporabljati bolniki s sladkorno boleznijo tipa 1 (od insulina odvisno sladkorno bolezen), ki nimajo nobenega C-peptida v krvi (označevalca sladkorne bolezni tipa 1).
The studies measured the level of a substance in the blood called glycosylated haemoglobin (HbA1c) which gives an indication of how well the blood glucose is controlled.
V študijah so merili vrednost snovi v krvi, imenovane glikirani hemoglobin (HbA1c), ki je pokazatelj stopnje uravnavanja glukoze v krvi.
For the full list of all side effects seen with Prandin, see the Package Leaflet.
Za celoten seznam vseh neželenih učinkov, o katerih so poročali pri uporabi zdravila Prandin, glejte navodilo za uporabo.
In all studies, Prandin led to a decrease in the level of HbA1c, which showed that blood glucose levels had been controlled to a similar level to that seen with the comparator medicines.
V vseh študijah je zdravilo Prandin povzročilo znižanje vrednosti HbA1c, kar kaže, da so bile koncentracije glukoze v krvi uravnane v podobnem obsegu kot pri primerjalnih zdravilih.
Prandin is used in patients who have type 2 diabetes (non-insulin-dependent diabetes).
Zdravilo Prandin se uporablja pri bolnikih s sladkorno boleznijo tipa 2 (sladkorno boleznijo, ki ni odvisna od insulina).
It is used together with diet and exercise to lower blood glucose (sugar) levels in patients whose hyperglycaemia (high blood glucose levels) cannot be controlled by diet, weight reduction and exercise.
Uporablja se skupaj z dieto in telesno dejavnostjo za znižanje glukoze (sladkorja) v krvi pri bolnikih, pri katerih hiperglikemije (visoke koncentracije glukoze v krvi) ni mogoče uravnavati z dieto, zmanjšanjem telesne mase in telesno dejavnostjo.
Prandin helps the pancreas to produce more insulin at mealtimes and is used to control type 2 diabetes.
Zdravilo Prandin pomaga trebušni slinavki, da tvori več insulina ob obrokih in se uporablja za uravnavanje sladkorne bolezni tipa 2.
Prandin can also be used for type 2 diabetes patients whose blood glucose levels are usually controlled well on diet, but are experiencing temporary loss of blood glucose control.
Zdravilo Prandin se lahko uporabi tudi pri bolnikih s sladkorno boleznijo tipa 2, pri katerih so koncentracije glukoze v krvi običajno dobro uravnane z dieto, vendar občasno doživijo izgubo nadzora nad glukozo v krvi.
Prandin may also be used with metformin (another anti-diabetes medicine) in type 2 diabetes patients whose blood glucose levels are not satisfactorily controlled on metformin alone.
Zdravilo Prandin se lahko uporablja tudi z metforminom (drugim antidiabetičnim zdravilom) pri bolnikih s sladkorno boleznijo tipa 2, pri katerih koncentracije glukoze v krvi ni mogoče zadovoljivo uravnavati samo z metforminom.
Prandin produced a good insulin response to a meal within 30 minutes of being dosed in type 2 diabetes patients, leading to a blood glucose-lowering effect throughout the meal.
Pri bolnikih s sladkorno boleznijo tipa 2 se je v 30 minutah po odmerku zdravila Prandin pojavil dober odziv insulina na obrok, kar je povzročilo znižanje glukoze v krvi v celotnem obdobju obroka.
The full EPAR for Prandin is available here.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Prandin je na voljo tukaj.
How does Prandin work?
Kako zdravilo Prandin deluje?
What is Prandin used for?
Za kaj se uporablja zdravilo Prandin?
What is Prandin?
Kaj je zdravilo Prandin?
How is Prandin used?
Kako se zdravilo Prandin uporablja?
How has Prandin been studied?
Kako je bilo zdravilo Prandin raziskano?
The full list is available in the Package Leaflet.
Za celoten seznam glejte navodilo za uporabo.
This overview was last updated in 06-2019
Pregled je bil nazadnje posodobljen 06-2019.
Further information on Miglustat Dipharma can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/miglustat-dipharma.
Nadaljnje informacije o zdravilu Miglustat Dipharma so na voljo na spletni strani agencije: ema.europa.eu/medicines/human/EPAR/ziextenzo.
Miglustat Dipharma received a marketing authorisation valid throughout the EU on 18 February 2019.
Za zdravilo Miglustat Dipharma je bilo 18. februarja 2019 izdano dovoljenje za promet, veljavno po vsej Evropski uniji.
These include loss of coordination, problems with ‘saccadic' (rapid) eye movements that can lead to impaired vision, delayed development, difficulty swallowing, decreased muscle tone, fits and learning difficulties.
Med njimi so izguba koordinacije, težave s „sakadnim“ (hitrim) gibanjem oči, ki lahko vodi v motnje vida, zapoznel razvoj, težave pri požiranju, zmanjšan mišični tonus, epileptični napadi in učne težave.
The company also carried out a study that showed that it is ‘bioequivalent' to the reference medicine.
Izvedlo je tudi študijo, ki je pokazala, da je zdravilo „bioekvivalentno“ referenčnemu zdravilu.
• adults (aged 18 years and above) with mild to moderate type-1 Gaucher disease.
• odraslih (starejših od 18 let) z blago do zmerno obliko Gaucherjeve bolezni tipa-1.
What measures are being taken to ensure the safe and effective use of Miglustat Dipharma?
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Miglustat Dipharma?
Because Miglustat Dipharma is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Ker je zdravilo Miglustat Dipharma generično zdravilo in je bioekvivalentno referenčnemu zdravilu, so njegove koristi in tveganja enaki kot pri referenčnem zdravilu.
Miglustat Dipharma is used to treat the neurological symptoms of the disease (symptoms affecting the brain and nerves).
Zdravilo Miglustat Dipharma se uporablja za zdravljenje nevroloških simptomov bolezni (simptomov, ki prizadenejo možgane in živce).
• patients of all ages with Niemann-Pick type-C disease, a potentially fatal disease in which glycosphingolipids build up within cells in the brain and elsewhere in the body.
• bolnikov vseh starosti z Niemann-Pickovo boleznijo tipa-C, ki je lahko smrtna in pri kateri se glikosfingolipidi kopičijo v celicah v možganih in drugod v telesu.
The European Medicines Agency concluded that, in accordance with EU requirements, Miglustat Dipharma has been shown to have comparable quality and to be bioequivalent to Zavesca.
Evropska agencija za zdravila je zaključila, da je bilo v skladu z zahtevami EU dokazano, da ima zdravilo Miglustat Dipharma primerljivo raven kakovosti kot referenčno zdravilo Zavesca ter da mu je bioekvivalentno.
Side effects reported with Miglustat Dipharma are carefully evaluated and any necessary action taken to protect patients.
Neželeni učinki, o katerih so poročali pri zdravilu Miglustat Dipharma, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
As for every medicine, the company provided studies on the quality of Miglustat Dipharma.
Tako kot za vsako zdravilo, je podjetje predložilo študije o kakovosti zdravila Miglustat Dipharma.
Studies on the benefits and risks of the active substance in Gaucher disease have already been carried out with the reference medicine, Zavesca, and do not need to be repeated for Miglustat Dipharma.
Študije o koristih in tveganjih učinkovine pri Gaucherjevi bolezni so že bile izvedene z referenčnim zdravilom Zavesca, zato jih ni treba ponoviti za zdravilo Miglustat Dipharma.
This enzyme is involved in the first step of the production of glucosylceramide.
Ta encim sodeluje na prvi stopnji tvorbe glukozilceramida.
Miglustat Dipharma is used in patients who cannot receive the standard treatment of enzymereplacement therapy (ERT);
Zdravilo Miglustat Dipharma se uporablja pri bolnikih, ki ne morejo prejemati običajnega encimskega nadomestnega zdravljenja (ERT);
An overview of Miglustat Dipharma and why it is authorised in the EU
Pregled zdravila Miglustat Dipharma in zakaj je odobreno v EU
As for all medicines, data on the use of Miglustat Dipharma are continuously monitored.
Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Miglustat Dipharma stalno spremljajo.
For more information about using Miglustat Dipharma, see the package leaflet or contact your doctor or pharmacist.
Za več informacij o uporabi zdravila Miglustat Dipharma glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Miglustat Dipharma have been included in the summary of product characteristics and the package leaflet.
Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Miglustat Dipharma upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo.
Miglustat Dipharma is used to treat the following patients:
Zdravilo Miglustat Dipharma se uporablja za zdravljenje naslednjih bolnikov:
Miglustat Dipharma is intended for long-term use.
Zdravilo Miglustat Dipharma je namenjeno za dolgotrajno uporabo.
Both diseases cause a build-up of fatty substances called glycosphingolipids in the body.
Obe bolezni povzročata kopičenje maščobnih snovi, imenovanih glikosfingolipidi, v telesu.
By preventing the enzyme from working, miglustat can reduce the production of glucosylceramide in cells, thereby reducing the symptoms of type-1 Gaucher disease.
Miglustat lahko s preprečevanjem delovanja encima zmanjša tvorbo glukozilceramida v celicah in s tem zmanjša simptome Gaucherjeve bolezni tipa-1.
What are the benefits and risks of Miglustat Dipharma?
Kakšne so koristi in tveganja zdravila Miglustat Dipharma?
This means that Miglustat Dipharma contains the same active substance and works in the same way as a ‘reference medicine' already authorised in the EU called Zavesca.
To pomeni, da vsebuje enako učinkovino in deluje na enak način kot „referenčno zdravilo“, ki je že odobreno v EU in se imenuje Zavesca.
What is Miglustat Dipharma and what is it used for?
Kaj je zdravilo Miglustat Dipharma in za kaj se uporablja?
Patients with this disease lack an enzyme called glucocerebrosidase, which results in a glycosphingolipid called glucosylceramide building up in different parts of the body, such as the spleen, liver and bones.
Bolnikom s to boleznijo primanjkuje encima, imenovanega glukocerebrozidaza, zaradi česar se glikosfingolipid, imenovan glukozilceramid, kopiči v različnih delih telesa, kot so vranica, jetra in kosti.
Miglustat Dipharma is available as 100 mg capsules to be taken by mouth.
Zdravilo Miglustat Dipharma je na voljo v obliki 100-miligramskih kapsul, ki se jemljejo peroralno.
Why is Miglustat Dipharma authorised in the EU?
Zakaj je bilo zdravilo Miglustat Dipharma odobreno v EU?
Miglustat Dipharma is a ‘generic medicine'.
Zdravilo Miglustat Dipharma je „generično zdravilo“.
For Niemann-Pick type-C disease, it is two capsules three times a day for patients aged 12 years and over; in younger patients, the dose depends on their weight and height.
Priporočeni začetni odmerek za Gaucherjevo bolezen tipa-1 je ena kapsula trikrat na dan. Priporočeni začetni odmerek za Niemann-Pickovo boleznijo tipa-C sta dve kapsuli trikrat na dan za bolnike, starejše od 12 let; odmerek pri mlajših bolnikih je odvisen od njihove telesne mase in višine.
Other information about Miglustat Dipharma
Druge informacije o zdravilu Miglustat Dipharma
The medicine can only be obtained with a prescription and treatment should be supervised by doctors who are experienced in the management of Gaucher disease.
Predpisovanje in izdaja zdravila Miglustat Dipharma je le na recept, zdravljenje z njim pa mora nadzorovati zdravnik, ki ima izkušnje z zdravljenjem bolnikov z Gaucherjevo boleznijo.
Miglustat Dipharma is used to treat two inherited diseases that affect the way the body handles fats.
Zdravilo Miglustat Dipharma se uporablja za zdravljenje dveh dednih bolezni, ki vplivata na način presnove maščob v telesu.
The active substance in Miglustat Dipharma, miglustat, blocks an enzyme called glucosylceramide synthase.
Učinkovina zdravila Miglustat Dipharma, miglustat, preprečuje delovanje encima, imenovanega glukozilceramidsintaza.
Therefore, the Agency's view was that, as for Zavesca, the benefit of Miglustat Dipharma outweighs the identified risk and it can be authorised for use in the EU.
Zato je menila, da koristi zdravila Miglustat Dipharma enako kot pri zdravilu Zavesca odtehtajo znana tveganja in da se zdravilo lahko odobri v EU.
How does Miglustat Dipharma work?
Kako zdravilo Miglustat Dipharma deluje?
How has Miglustat Dipharma been studied?
Kako je bilo zdravilo Miglustat Dipharma raziskano?
How is Miglustat Dipharma used?
Kako se zdravilo Miglustat Dipharma uporablja?